Fully human antibodies and fragments recognizing human c-Met
US10407503B2 · kind B2 · utility
0Cited by
11References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2013 |
| Grant date | Sep 10, 2019 |
| Priority date | — |
| Expiry date | Mar 29, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/91205
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human antibody fragments against c-Met have been identified through phage display technology. The high affinity and low immunogenicity make them very useful for both in vivo and in vitro applications. These novel human antibodies can greatly help the study of drug resistance in EGFR targeted therapies, and improve the diagnosis and treatment of cancer patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.